Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.

• Cancer-associated thrombosis is a major health problem that affects morbidity and mortality of people with cancer. • Surgical and systemic pharmacological anticancer treatments have a significant impact on the thrombotic risk of patients. • Primary thromboprophylaxis may be considered in high-risk ambulatory cancer patients using validated risk models. • Anticoagulant treatment of VTE in cancer patients is effective but may be associated with increased bleeding. • LMWH or DOACs are effective treatments and generally safe options for cancer-associated thrombosis. [ABSTRACT FROM AUTHOR]